ONCOLOGY AND HAEMATOLOGY

**G81** EFFECTS OF GROWTH HORMONE TREATMENT ON SELF-ESTEEM AND MOOD IN CANCER SURVIVORS WHO ARE GROWTH HORMONE DEFICIENT

Lamming CED*, Butler GE** and Picton SV***. "Children's Cancer Research Centre, University of Minnesota, Minneapolis, USA,*"Leeds General Infirmary, **"St James' University Hospital, Leeds.

Aim: To investigate the effects of commencing growth hormone treatment, in growth hormone deficient cancer survivors, on selected measures of body image, self-esteem and mood.

Method: 21 Patients aged between 8 and 18 years who were starting growth hormone replacement were recruited from childhood cancer survivors in the Yorkshire and Trent regions. Disfigured and significantly disabled patients were excluded from this study. Questionnaires were administered before and 8 to 10 weeks after starting growth hormone replacement therapy. Battle and Harter scores were used for self-esteem and PANAS scores for mood respectively. The study received ethical approval from St James University Hospital.

Results: All patients who were recruited completed the study. The mean pre-treatment standard deviation score for height was +2.0. At assessment there was a slight improvement in the score (+1.8) but this was not significant statistically.

Self-esteem: The mean pre-treatment Battle score was 45 (SD 7.7), the mean post-treatment score was 63 (SD 7.2). There was a significant improvement (P<0.001) on paired t Testing. On the Harter scale only the Global Self Worth subsection (P<0.01) showed any significant change. The correlation coefficient for Harter versus Battle was 0.89 showing the Battle score to be a reliable assessment tool in this group of patients.

Mood: The PANAS measures positive and negative aspects of mood. The positive mood scores showed a significant improvement with pre-treatment mean (27.4) versus post-treatment mean (35.3), p<0.01 for paired t Tests. Negative mood scores fell (pre-treatment mean 14.4 and post-treatment mean 13.9) but this change was not statistically significant.

Conclusions: Initiation of growth hormone therapy leads to significant early improvements in measures of mood and self-esteem before the physical effects of therapy occur.

**G82** COCHRANE REVIEW: THE PREVENTION OF MUCOSITIS AND ORAL CANDIDIASIS FOR PATIENTS WITH CANCER

JE Clarkson*, HV Worthington†, OB Eden* †Cochrane Oral Health Group, *Christie Hospital Manchester

Aims: This systematic review of randomised trials aimed to determine whether oral agents are superior to placebo in treating oral mucositis and candidiasis for cancer patients.

Methods: We reviewed randomised trials of cancer patients receiving prophylactic oral therapy, searching computerised Medline, Embase, Cinahl, Cancerlit, the Cochrane controlled trials register and oral health group specialist register up until July 1999. Authors of eligible studies were contacted to confirm trial data and obtain additional information.

Results: Of 1605 abstracts and 108 papers identified only 26 studies were truly randomised. 11 were included in the meta-analysis for mucositis. Of the six prophylactic agents used only ice chips were effective (relative risk 0.57, 95% CI 0.43 to 0.77). The number needed to treat (NNT) to prevent one extra case of mucositis was 4 (95% CI 3-7). 15 studies were included for oral candidiasis. Non-absorbable anti-fungal agents were not effective; those partially or fully absorbed were capable of preventing oral candidiasis with partially absorbed more effective (relative risk 0.13, 95% CI 0.06 to 0.27) with an NNT to prevent one extra case of 3 (95% CI 3-6).

Conclusions: Ice chips may prevent mucositis, and prophylactic absorbed or partially absorbed anti-fungals can reduce overt candidiasis. There is little evidence to support the use of standard therapy with oral nystatin.

**G83** THE USE OF MAGNETIC RESONANCE IMAGING IN DETECTING BONE MARROW DISEASE IN NEUROBLASTOMA

*Departments of Haematology/Oncology and **Radiotherapy, Royal Manchester Children's Hospital, Manchester M27 4HA

Many operators do not obtain adequate bone marrow biopsy specimens, in particular in infants. We therefore evaluated the ability of magnetic resonance imaging (MRI), at diagnosis, to detect bone marrow metastases in 25 children with neuroblastoma and compared it with bone marrow aspiration and biopsy. Previous studies had demonstrated the ability of MRI in detecting bone marrow involvement in multiple myeloma. Bone marrow aspirates and biopsies, and MRI were retrospectively assessed and graded by the consensus of two independent observers. Bone marrow involvement and adequacy by NW and NW respectively. Twelve of the 43 (28%) bone marrow biopsies available were inadequate and in 16 patients bone marrow biopsies and/or aspirates demonstrated metastases. In 12 of these 16 patients MRI demonstrated infiltration with neuroblastoma. No MRI showed evidence of infiltration without metastases in either their aspirate or biopsy, hence MRI had a sensitivity in detecting bone marrow disease in neuroblastoma of 75% with a specificity of 100%. We conclude that MRI is highly specific in detecting bone marrow metastases and may add to bone marrow aspirates and biopsies, particularly in infants. As the MRI were not specifically performed to assess marrow disease further prospective studies are required to assess if the sensitivity of MRI can be improved.

**G84** THE USE OF DISTORTION PRODUCT OTOACUSTIC EMISSIONS IN SCREENING FOR DRUG INDUCED HIGH FREQUENCY HEARING LOSS

Lynda Brook, Jean Trussell*, Hope Forsythe*, Barry Pizer Department of Paediatric Otolaryngology, *Department of Paediatric Audiology, Alder Hey Children's Hospital, Liverpool

High frequency hearing loss is an important complication of treatment with drugs such as platinum chemotherapeutic agents. Early high frequency hearing loss is often difficult to demonstrate in young or sick children who cannot co-operate purely tone audiometry (PTA).

Distortion product otoacoustic emissions (DPOAE) are sounds generated by the precise cochlear structure affected by ototoxic drugs. DPOAE are detected by a non-invasive technique, requiring minimal patient co-operation. There have previously been no significant clinical studies of DPOAE in normal children or those receiving ototoxic drugs.

Normal data were collected from a control group of 102 children. Risk factors for sensorineural hearing loss and middle ear disease were excluded. Assessment included PTA (or age appropriate techniques), DPOAE growth rates and DP-grams. This control data was then used to evaluate the results of a prospective group of 36 children receiving platinum chemotherapy and a retrospective group of 55 children previously treated with platinum agents.

Twenty-six children (21 retrospective and 5 prospective) had evidence of significant high frequency hearing loss (PTA threshold >40dB at or above 4kHz) with corresponding loss of DPOAE at the affected frequencies in all patients. Children studied prospectively demonstrated a significant decrease in amplitude of DPOAE before DPOAE disappeared and before there was a change in PTA threshold (paired t test p<0.05). 8 children with normal PTA showed abnormal DPOAEs. These children had higher cumulative drug doses and may represent a group with early cochlear damage.

DPOAE provide a feasible, frequency specific, test of cochlear function in children with the potential to detect early cochlear damage at a stage when action to reduce the severity of hearing loss may be possible.

**G85** RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (rTPA) THERAPY FOR HEPATIC VENO-OCCCLUSIVE DISEASE (VOD)

Baiwa RPS, Skinner R, Flood TJ, Abinun M, Cant AJ Children's Bone Marrow Transplantation Unit, Newcastle General Hospital, Newcastle, UK

VOD is a common early complication of Bone Marrow Transplantation (BMT), and when severe has a very high mortality. rTPA has been used to treat severe VOD, but little information about its use is available in children. Over 3 years we have given rTPA to 10 patients (pt) (age 2 months-14 years) with severe VOD after allologenic or autologous BMT for congenital immunodeficiency (8pt) or neoplasms (2). Conditioning containing all pt. Treatment with rTPA was started when the predicted risk of developing severe VOD was >30% (using the Bearman model, plotting bilirubin (bili) against % weight gain). All 10 pt were given rTPA, 0.2 mg/kg/day for 4 days, and Heparin 5 units/kg/hour for 10 days. rTPA was commenced between day +5 and +19, for given for 4-11 days and the dose doubled in 5 pt after 4 days. Mean peak bili was 315 (range 21-832) μmol/l, 5 pt required abdominal paracentesis, 3 also needed cardio-respiratory and renal support. rTPA responded with resolution of clinical and biochemical signs by day +61; 1 of these had anicteric VOD with tender hepatomegaly, gross ascites and 19% weight gain. 3 pt with Omenn's syn-drome died from multorgan failure (MOF), but bili had decreased to <80 μmol/l in 2 after rTPA; capillary leak syndrome leading to respiratory and renal failure, rather than liver damage was the major factor leading to death. 1 patient failed to respond to rTPA and died after a liver biopsy, which confirmed severe VOD. The other pt stabilised initially after starting rTPA, but then had progressive liver failure due to biopsy proven acute GVHD. rTPA was stopped in 1 pt after 7 days because of worsening of pre-existing gastrointestinal bleeding. No other toxicity due to rTPA was seen. Overall 7 of 9 patients with VOD showed improvement after rTPA was started and 5 recovered fully, rTPA and heparin may be an effective treatment for severe VOD if started before development of MOF.
G86 NEUROBLASTOMA TUMOURS WITHOUT MYCN AMPLIFICATION AND WITH LOSS OF HETEROZYGOSITY AT CHROMOSOMAL SEGMENTS COMPRISING A DISTINCT GROUP OF AGGRESSIVE TUMOURS
Oude Luttikhuis MEM, Rees SA, Powell JE, McConville CM University of Birmingham and Birmingham Children’s Hospital, Birmingham B15 2TT

Amongst the heterogeneous group of neuroblastoma tumours, stage 3 and 4 tumours and especially those with MYCN amplification and loss of heterozygosity (LOH) at 1p are associated with a poor survival rate. We investigated whether chromosomal abnormalities other than MYCN and LOH at 1p may be involved in the aggressive behaviour of the tumour. LOH and CGH studies report that loss of heterozygosity is most frequent at the chromosomal regions 3p, 4p, 11q and 14q. Therefore we studied 25 tumours for LOH at these regions. The tumours comprise 8 stage 1, 1 stage 2, 1 stage 4S, 2 stage 3 and 12 stage 4 and stage was unknown in 1. MYCN amplification was observed in 6 tumours. Matched pairs of tumour and constitutional DNA were analysed using polymorphic markers on 3p21.3-3p23.3, 4p16.1, 11q13.3-11q24.2 and 14q32.11-14q32.32. In 10 tumours (40%) LOH at 11q was observed accompanied by LOH at 1 or more of the chromosomal regions 3p, 4p or 14q in 7 of those. LOH at 11q occurred in non-MYCN amplified tumours only, often stage 3 or 4. Our data showed that among patients without MYCN amplification, those with deletion of 11q had a significantly worse outcome. Taken together, a group of aggressive neuroblastoma tumours are characterised by absence of MYCN amplification and LOH at 11q often accompanied by LOH at 3p, 4p or 14q.

G87 ETOTOSISUDE-INDUCED CLEAVAGE OF THE MLL GENE: POTENTIAL APPLICAPN IN PREDICTING INDIVIDUAL SENSITIVITY TO TOPOSISOMERASE 2 INHIBITOR THERAPY IN CHILDHOOD CANCER
Na A1-2, Taylor GM1 and Eden OB1 Immunogenetics Laboratory, St Mary’s Hospital2, Academic Unit of Paediatric Oncology, Christie and Royal Manchester Children’s Hospital2

Treatment-related leukaemia (TRL) is a growing and the most serious complication of effective childhood cancer chemotherapy with topoisomerase 2 (topo-2) inhibitors such as etoposide. These TRLs frequently carry rearrangement of the Mixed Lineage Leukaemia (MLL) gene, resulting from drug-induced gene cleavage. Molecular analysis of MLL cleavage may offer a way to determine and compare patient sensitivity to topo-2 inhibitor therapy and indirectly predict the risk of TRL.

We have studied cleavage in the Breakpoint Cluster Region (BCR) of the MLL gene in normal lymphoid and leukaemic cell lines exposed to etoposide using a hybridization assay with a cDNA probe. MLL cleavage fragments were quantified by real-time autoradiography. Etoposide concentrations and exposure times for maximal MLL cleavage were determined for each cell line and their sensitivity to etoposide was estimated and compared.

Two MLL cleavage fragments (~6.8 and 1.9kbp) were consistently induced in vitro by etoposide. The combined size of these fragments suggested that most cleavage occurred at a specific site in the BCR and was consistent with double-strand DNA breakage. The proportion of cleavage fragments ranged from 30-80% of total MCL BCR signals. Exposure to etoposide of 10 μM for 5-7 hours gave maximal cleavage of the gene but differences were detected in the susceptibility of cell lines to MLL cleavage.

definition and quantification of etoposide-induced MLL cleavage has potential in predicting individual sensitivity to topo-2 inhibitors. Collection and analysis of blood and bone marrow samples from children receiving topo-2 inhibitor therapy are in progress.

G88 A COMMON PATHWAY OF DRUG RESISTANCE IN LEUKAEMIA?
Bailey S, Hall AG, Pearson ADP, Reid MM and Redfern CPF Child Health, University of Newcastle upon Tyne, England

Background: Glucocorticoids have been used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) for many years, initially as the only agent and then as part of multiagent chemotherapy in ALL and in CLL, either alone or with chlorambucil. In ALL 20% of patients are resistant to glucocorticoids at presentation but on relapse this rises to above 70%. The mechanism of this resistance remains unknown despite much work in this field, theories however abound which include alternative splicing of the glucocorticoid receptor, number of glucocorticoid receptors and inhibition of factors responsible for cell survival. Other agents used in the treatment of ALL include daunorubicin and in CLL chlorambucil and fludarabine.

Aim: To investigate whether there is cross-resistance between drugs with different mechanisms of action used in the treatment of haematological malignancies in the form of ALL and CLL.

Methods: In vitro sensitivity to glucocorticoids and daunorubicin in ALL and prednisolone, fludarabine and chlorambucil in CLL were measured using the MTT assay.

Results: MTT assays on 71 ALL samples were analyzed for LC50 values to prednisolone and daunorubicin in ALL. The LC50 values for these 2 drugs in the same sample showed a strong correlation (r= 0.52, p<0.0001). Blasts from 46 patients with CLL were analyzed, in vitro sensitivity of prednisolone strongly correlated with both fludarabine (r= 0.631, p<0.001) and chlorambucil (r= 0.692, p<0.0001). Sensitivity to chlorambucil and fludarabine also correlated (r= 0.692, p<0.0001).

Conclusion: These data show that sensitivity of leukaemic blasts to in vitro drugs suggests a common mechanism of resistance despite their different mechanisms of action. This is likely to involve downstream aspects of the apoptotic pathway.

G89 TEMPORAL INCREASE IN THE INCIDENCE OF CHILDHOOD PEAK COMMON ACUTE LYMPHOBLASTIC LEUKAEMIA (c-ALL) SEEN IN NORTH WEST ENGLAND
McNally RJ1, Birch JM, Taylor GM, Eden OB2 CRCA PaeDiatric & Familial Cancer Research Group, Royal Manchester Children’s Hospital, Manchester M27 4HA

Aims: To examine temporal trends in incidence in acute leukaemia by age,sex and immunophenotype.

Methods: Cases were ascertained from the Manchester Children’s Tumour Registry. Immunophenotyping is available for all cases since 1980. Incidence rates were calculated using annual mid-year population estimates as denominators. Log-linear modelling was used to analyse temporal trends.

Results: Out of 435 cases of ALL diagnosed between 1980 and 1998, 339 were classified as precursor B-cell ALL(c-ALL),52 T-ALL,31 Null-ALL and 13 other. There was significant increase of 2.0% per annum in the childhood peak of c-ALL (ages 1-4y,0.025). Female rates increased more rapidly than male (3.6% versus 2.6% per annum). There was no increase in other age-groups for c-ALL, nor in other sub-groups of leukemias.

Conclusions: These observations suggest that c-ALL has a different aetiology to other subtypes of childhood leukaemia. Recent observations suggest that involvement of infections in the aetiology of c-ALL. If the observed increase is due to such a mechanism it is unlikely to involve a new infection. More probably there has been a change in patterns of exposure.

G90 THROMBOCYTOPENIA WITH ABSENT RADI (TAR) SYNDROME: NOMINALLY A HAEMATOLOGICAL SYNDROME IN WHICH MALIGNANCY AND GASTRO-INTESTINAL PROBLEMS PREDOMINATE
Ancliff PJ1, Hann IM, Khair K, Lieners R Department of Haematology, Great Ormond Street Hospital, London

We present a series of 6 TAR patients who presented to our institution over the past ten years. Summary of haematological data:

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Platelet count (birth) x10^11</th>
<th>Months until plt&lt;40</th>
<th>Significant bleed</th>
<th>Prophylactic plt support</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>46 (19 at 2/52)</td>
<td>22</td>
<td>Nil</td>
<td>nil</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>30</td>
<td>PV bleed*</td>
<td>3 months</td>
</tr>
<tr>
<td>6</td>
<td>15</td>
<td>39</td>
<td>Nil</td>
<td>nil</td>
</tr>
<tr>
<td>6</td>
<td>26</td>
<td>15</td>
<td>Nil</td>
<td>nil</td>
</tr>
<tr>
<td>10</td>
<td>N/A</td>
<td>8</td>
<td>Nil</td>
<td>nil</td>
</tr>
<tr>
<td>9</td>
<td>96</td>
<td>Intracranial</td>
<td>9 months</td>
<td>nil</td>
</tr>
</tbody>
</table>

*Possibly just “normal” loss in first week of life. Transfused before referral.
*Fall from 1.3m window—full recovery with conservative management.

All patients had bilateral radial aplasia, 1 had true phacomelia of the arms. have marked deformities of the lower limbs that have required & will require further operation. One cannot yet walk because of his disabilities.

Varying degrees of cow’s milk intolerance were present in 6/7 cases. All appeared to settle over the first few years of life, although the final case required naso-gastric feeding in infancy for a steroid-responsive enteropathy. All appear to be developing normally & have remarkable function in their upper limbs. All have required orthopaedic surgery to maximise function. This has been performed safely with appropriate donor platelet count.

Conclusions: TAR is a multi-system disease in which non-haematological problems may dominate. Failure to thrive is common & may represent food intolerance or more severe gut disease. The platelet count eventually reaches a safe level. The mortality figures of 25% in the literature are no longer justified. Prophylactic platelet support is not usually necessary & may be dangerous because of allo-immunslation. HLA matched platelets should be considered in this situation. Corrective surgery is safe & appropriate.

G91 ASSESSING THE IMPACT OF GUIDELINES IN THE REQUESTS FOR COMMON HAEMATOLOGICAL INVESTIGATIONS
Shrivastava A, Kuna J Southend Hospital NHS Trust, Southend on Sea, UK

Introduction: Requests for common haematological investigations i.e. full blood count (FBC), Urea and Electrolytes (U&E’s and C-Reactive Protein (CRP) have been increasing by mean of 20% each year over the previous 2 years in the Paediatric Department of our District General Hospital. However, no significant rises have been observed in the number of patients seen. The first six months of 1997 saw a request of the above investigations asked in
almost every third child seen in the department. Guidelines were therefore put in place and the aim of this prospective study was to determine the impact of such guidelines on future requests for the above investigations.

**Methods:** Requests for FBC, U&E’s and CRP were monitored for a period of 10 months from August 1997 until May 1998.

**Results:** The number of patients in the Paediatric Department recorded a rise of 31.3% during the period of study. However, requests for FBC decreased by median 21.7% (range 16% - 24%), U&E’s by median 38.2% (range 7% - 47%) and CRP by median 26.3% (range 10% - 38%). These were significant decreases (P<0.05). Requests for other haematological investigations i.e. blood cultures, serum bone profile and liver function tests also recorded significant falls (P<0.05). Mean number of hospital admissions as a measure of morbidity were not significantly affected (P>0.2).

**Conclusions:** Significant reductions in the requests for common haematological investigations can be achieved. Such changes in practice could potentially result in less invasive procedures associated with considerable parental anxiety and hospital costs.

**USE OR ABUSE OF BLOOD PRODUCTS: ARE WE USING VALUABLE RESOURCES PROPERLY?**

Bolton-Maggs PHB, Finningan L, Wright A Royal Liverpool Children’s Hospital, Alder Hey, Eaton Road, Liverpool L12 2AP

**Aims:** To trace the fate of all platelets and fresh frozen plasma issued from the hospital blood bank over a 6 month period to assess the indications for use and the standard of documentation.

**Methods:** Two audit personnel collected records of units issued from the blood bank and followed their fate by examination of patient case notes. Data was collected on a standardised proforma and analysed using Microsoft Access.

**Results:** FFP - 115 orders were made for 81 patients; a total of 176 units were issued, 83% for cardiac surgery. 42 units (24%) were wasted, reasons unclear. Documentation was incomplete in a significant number, in particular 24% had no doctor’s signature and only 29% had a record of the volume given. The rationale for transfusion of FFP was not clearly documented.

Platelets: 364 orders were made for 123 children; 514 packs were issued of which only 337 (64%) were transfused. 67% of the wasted units were ordered electively for cardiac surgery, and 23% were for oncology patients. Transfusion documentation was moderate, but 20% had no doctor’s signature. Indication for transfusion was most commonly a low platelet count with or without bleeding.

**Conclusions:** An unacceptable wastage of both FFP and platelets is occurring. Documentation of indications needs to be more explicit. Discussion with cardiac staff led to an immediate change in platelet ordering policy for elective cardiac operations leading to a significant reduction in the wastage of platelets. Changes in procedures on the ward also led to rationalisation and a reduction due to over-ordering, particularly at weekends.

**CANCER PHENOTYPE ASSOCIATED WITH GERMLINE TP53 MUTATIONS: AN ANALYSIS OF 28 KINDREDS**

Birch JMB, Alston RD, McNally RJQ, Kelsey AM, Eden OB, Evans DGR, Varley J CRC Paediatric & Familial Cancer Research Group, Royal Manchester Children’s Hospital, M27 4HA

**Aims:** To establish the frequencies of specific cancers, in families with germ-line TP53 mutations relative to population cancer rates.

**Methods:** A cohort of individuals including first and second degree relatives of probands from cancer-prone families with germ-line TP53 mutations was established. Expected numbers of cancers were estimated from age,sex and morphological type-specific cancer registry rates and compared with the observed. Log-linear modelling was used to compare distributions of cancers in the families with those in the general population.

**Results:** The cancer distributions in TP53 mutation-carrying families was highly significantly different from the general population both for childhood (p<0.0005) and adult [p<0.0005] onset cancers. The main paediatric cancers were embryonal rhabdomyosarcoma (22%) and high grade gliomas (16%) adrenocortical carcinoma (67%) of children who survived their first cancer developed a second malignancy.

**Conclusion:** The effect of a germ-line TP53 mutation is not simply to increase the risk of all cancers, there is a tissue-specific cancer phenotype. The risk of multiple primary cancers is extremely high. Determination of constitutional TP53 status is of clinical importance in certain childhood cancers.